Intrexon | XON - Sales Revenues


Intrexon reported $717K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 8.62B 1.28B Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
MannKind USD 90.2M 21.76M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Veracyte USD 139.07M 1.53M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026